Download Files:
ACT-1004-1239
$650 – $5,400
Products Details
Product Description
– ACT-1004-1239 is a potent, selective, orally available CXCR7 antagonist with an IC50 value of 3.2 nM.
Web ID
– HY-142617
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C27H28F2N6O3
References
– [1]Richard-Bildstein S, et al. Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239. J Med Chem. 2020 Dec 24;63(24):15864-15882.
CAS Number
– 2178049-58-4
Molecular Weight
– 522.55
Compound Purity
– 99.80
SMILES
– O=C([C@H]1CN(CC2CC2)CC[C@@H]1NC(C3=NOC(C4=CC=C(F)C=C4F)=C3)=O)NC5(C6=NC=CC=N6)CC5
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : 20 mg/mL (ultrasonic)
Target
– CXCR
Isoform
– CXCR7
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
